Managing diabetes in frail patients is complex due to varying clinical factors. The optimal HbA1c target for each level of frailty remains unclear. Existing thresholds are based on expert opinion, but evidence guiding individualized targets by frailty severity is limited.1. What is the association between diabetes control and mortality among community-dwelling frail older adults. 2. What is the optimal HbA1c target for each level of frailty.A retrospective cohort study of patients aged ≥75 with type 2 diabetes, insured by Meuhedet Health Services (MHS), from 2015 to 2022. Inclusion required continuous enrollment in MHS, ≥2 years of medical history, ≥2 HbA1c values ≥6.5%, and at least one antidiabetic prescription. Exclusions were type 1 diabetes, missing recent HbA1c, and conditions affecting HbA1c reliability (e.g., G6PD deficiency, anemia, splenectomy). HbA1c category was defined using the most recent value in the year prior to cohort entry; frailty was assessed using a validated index based on ≥2 years of records. Follow-up began at age 75 and continued until death or December 31, 2024. The primary outcome was all-cause mortality. Analyses will be stratified by frailty level to explore the association between glycemic control and mortality across frailty categories. Statistical analysis included Cox proportional hazards models with HbA1c categorized as <7% (reference), 7–7.9%, and ≥8%, adjusting for age, sex, SES, diabetes duration, and insulin use. Effect modification by frailty was assessed using interaction terms and penalized splines. Kaplan-Meier curves and subgroup/sensitivity analyses were also performed.No results yet.No results yet.No results yet.